Clinical trials: Antipsychotic
Schizophrenia Disorder, Metabolic Syndrome
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
Patients with schizophrenia on second-generation antipsychotics have a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options.
- Conditions
- Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk
- Trial name
- NCT07770282
- Testing
- Semaglutide + TAU
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Sialorrhea
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
This study will evaluate the efficacy and safety of MYOBLOC in the treatment of Sialorrhea (drooling), which can be a symptom of many disease conditions. MYOBLOC will be injected directly into the salivary glands.
- Trial name
- MYSTICOL (NCT01994109)
- Testing
- MYOBLOC
- Where
- 34 sites in United States, Russia and 1 more
- Volunteers
- 187 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Schizophrenia, Psychotic Disorders
A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
The purpose of the study is to evaluate the maintained effectiveness of long-acting injectable risperidone (RISPERDAL® CONSTA™) compared with the previous treatment with oral olanzapine in non-acute subjects with schizophrenia or…
- Trial name
- NCT00216632
- Testing
- risperidone
- Volunteers
- 99 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Patient Noncompliance
Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic
Psychotropic medications are a cornerstone of treatment for individuals with schizophrenia and schizoaffective disorder, however rates of full or partial non-adherence can exceed 60%.
- Trial name
- CAE-L (NCT01152697)
- Testing
- haloperidol decanoate, haloperidol, Customized Adherence Enhancement
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia, Impaired Cognition
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
This study is being conducted to further investigate the safety of prolonged exposure to EVP-6124 in subjects with Schizophrenia receiving a stable dose of an atypical antipsychotic who completed double-blind treatment on studies…
- Trial name
- NCT01714713
- Testing
- EVP-6124
- Where
- 128 sites in United States, Argentina and 14 more
- Volunteers
- 830 people
- Sponsor
- FORUM Pharmaceuticals Inc
Oxytocin + Non Specific Counselling, Oxytocin + Social Skills Training
Administrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective Patients
The objectives of the study are: 1. To evaluate the effect of OT compared to placebo, as add-on to anti-psychotics, on social functioning in schizophrenia. 2.
- Conditions
- Oxytocin + Non Specific Counselling, Oxytocin + Social Skills Training, Placebo + Non Specific Counselling, Placebo + Social Skills Training
- Trial name
- OXY-S-01 (NCT01598623)
- Testing
- Oxytocin, Social Skills Training
- Where
- Israel
- Volunteers
- 48 people
- Sponsor
- Sheba Medical Center
Schizophrenia
Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia
The purpose of this study is to demonstrate the effectiveness of paliperidone palmitate in patients with Schizophrenia.
- Trial name
- NCT00589914
- Testing
- RISPERDAL CONSTA, Paliperidone palmitate
- Where
- 82 sites in United States, Austria and 12 more
- Volunteers
- 1,221 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Antipsychotic-induced Weight Gain (AIWG)
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
This Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic…
- Trial name
- NCT04524403
- Testing
- Miricorlilant
- Where
- 40 sites in United States
- Volunteers
- 150 people
- Sponsor
- Corcept Therapeutics
SCHIZOPHRENIA 1 (Disorder), Metabolic Abnormalities
Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders.
The aim of the present study is to evaluate the effectiveness of the addition of the postbiotic Pediococcus acidilactici (pA1c®HI) on amelioration of metabolic disturbances in patients with (FEP) or (SSD) treated with…
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Metabolic Abnormalities, Postbiotic Supplement
- Trial name
- GLUCOPSICO (NCT07371325)
- Testing
- Pediococcus acidilactici, pA1c®HI postbiotic supplementation taking participants, Atypical antipsychotics (AAP)
- Where
- Spain
- Volunteers
- 36 people
- Sponsor
- Manuel Jesús Cuesta Zurita
Mental Disorders, Metabolic Syndrome
Pharmacist-led Interventions in Psychiatric Patients
The goal of this intervention study is to examine the impact of pharmacist-led interventions in psychiatric patients initiating second-generation antipsychotic treatment.
- Trial name
- NCT07446218
- Testing
- Pharmacist monitoring and counseling to prevent or delay metabolic syndrome
- Where
- 2 sites in Pakistan
- Volunteers
- 148 people
- Sponsor
- University of Lahore
Schizophrenia
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been…
- Trial name
- NCT01157351
- Testing
- paliperidone, risperidone, haloperidole
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 450 people
- Sponsor
- Janssen Scientific Affairs, LLC
Bipolar I Disorder
Risperdal Consta for Bipolar Disorder
We recruited 50 consenting adult subjects with DSM-IV TR diagnoses of bipolar disorder who were about to initiate or switch their current antipsychotic agent.
- Trial name
- NCT00177164
- Testing
- Injectable Risperidone (Consta) or oral antipsychotic
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh
Medication Administered in Error, Antipsychotics and Neuroleptics Toxicity
Novel Application of Simulation for Providers to Overcome Decisional Gaps in High-risk Prescribing
This pilot project aims to reduce the prescribing of high-risk medications, such as antipsychotics and benzodiazepines, to hospitalized older adults. To accomplish this, this project consists of two phases.
- Trial name
- NCT04668248
- Testing
- Simulation, Online educational training
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Brigham and Women's Hospital
Psychotic Disorders
A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders
The primary purpose of the study is to compare therapy with antipsychotic medication (antipsychotic monotherapy or antipsychotic combination) versus no antipsychotic medication, and antipsychotic monotherapy versus antipsychotic…
- Trial name
- NCT05633108
- Testing
- No Intervention
- Where
- United Kingdom
- Volunteers
- 579,728 people
- Sponsor
- Eisai Co., Ltd.
Schizophrenia, Metabolic Syndrome
The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain
Schizophrenia and bipolar disorders are major public health problems. The second generation anti-psychotic drugs have efficacy for both positive and negative symptoms and a favorable risk profile as far as movement disorders.
- Conditions
- Schizophrenia, Metabolic Syndrome, Vitamin D Deficiency
- Trial name
- NCT02281162
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Creighton University
Drug-induced Extrapyramidal Side Effects
Extrapyramidal Side-Effects in Antipsychotic Drug Therapeutics
The project is aimed at addressing the fundamental issue in antipsychotic therapeutics -the balance between mental state benefits and neurological risks.The latter cannot be overestimated and clinical skills in themselves are…
- Trial name
- NCT02366897
- Testing
- Manus Sensor Pen
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- University of Edinburgh
Neutropenia
Hematological Effects of Atypical Antipsychotics (AAPs) in a Geriatric Population: What is the Role of 5-HT2 Receptors
White lineage abnormalities and in particular neutropenia and agranulocytosis are known and increasingly studied adverse effects of antipsychotics, particularly second generation.
- Trial name
- AAPs (NCT06107322)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Strasbourg, France
Schizophrenia
FYS Study: Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in Spain
The purpose of this study is to establish the relationship between performance of patients with schizophrenia and relationship with perceived quality of sleep.
- Trial name
- NCT01376492
- Testing
- Functioning assessment, Quality of sleep assessment
- Volunteers
- 709 people
- Sponsor
- Janssen-Cilag, S.A.
Autism Spectrum Disorder
Weight Management Intervention for Youth and Young Adults With Autism Spectrum Disorder
Psychotropic medications are the first-line treatment across several diagnostic categories encompassing severe mood disturbances and behavioral problems.
- Trial name
- ACORN-ASD (NCT03865719)
- Testing
- Healthy Habits for Life
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pittsburgh
Schizophrenia
European Long-acting Antipsychotics in Schizophrenia Trial-II
Schizophrenia is a chronic psychiatric illness with a heterogeneous disease course, varying from periods of symptomatic remission to relapse.
- Trial name
- EULAST-II (NCT05165316)
- Where
- Israel
- Volunteers
- 400 people
- Sponsor
- Rene Kahn